{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:26:56Z","timestamp":1792589216008,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.leukres.2016.11.002","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:30:17Z","timestamp":1478133017000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes"],"prefix":"10.1016","volume":"52","author":[{"given":"Naamit","family":"Deshet-Unger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Prutchi-Sagiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Maaravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Golishevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drorit","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.11.002_bib0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/snep.2002.35973","article-title":"New clinical practice guidelines for chronic kidney disease: a framework for K\/DOQI","volume":"22","author":"Patel","year":"2002","journal-title":"Semin. Nephrol."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2016.11.002_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-S1-6","article-title":"Update on erythropoiesis-stimulating agents and clinical trials in oncology","volume":"14","author":"Aapro","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2016.11.002_bib0015","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/1097-0142(19951201)76:11<2319::AID-CNCR2820761121>3.0.CO;2-U","article-title":"Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy","volume":"76","author":"Ludwig","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.11.002_bib0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.leukres.2012.04.017","article-title":"Erythropoietin: the swinging pendulum","volume":"36","author":"Oster","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.11.002_bib0025","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2010-08-300541","article-title":"American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"116","author":"Rizzo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V84.4.997.997","article-title":"Recombinant human erythropoietin and the anemia of cancer","volume":"84","author":"Spivak","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000087896","article-title":"Erythropoietin induced tumour mass reduction in murine lymphoproliferative models","volume":"114","author":"Katz","year":"2005","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0040","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/eji.200637025","article-title":"Erythropoietin enhances immune responses in mice","volume":"37","author":"Katz","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0045","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.081275298","article-title":"Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models","volume":"98","author":"Mittelman","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2016.11.002_bib0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.0902-4441.2003.00190.x","article-title":"Erythropoietin has an anti-myeloma effect\u2014 a hypothesis based on a clinical observation supported by animal studies","volume":"72","author":"Mittelman","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2141.2006.06366.x","article-title":"Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease","volume":"135","author":"Prutchi-Sagiv","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2141.2009.07921.x","article-title":"Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes","volume":"148","author":"Alfinito","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0065","first-page":"150","article-title":"Immunological abnormalities in myelodysplastic syndromes","volume":"33","author":"Hamblin","year":"1996","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0145-2126(02)00173-X","article-title":"Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia","volume":"27","author":"Matsutani","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.11.002_bib0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/14740338.2011.534456","article-title":"Immune alterations in untreated and treated myelodysplastic syndrome","volume":"10","author":"Mewawalla","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.leukres.2016.11.002_bib0080","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2004-10-3872","article-title":"Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF","volume":"106","author":"Jadersten","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0090","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0095","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2006.06070.x","article-title":"High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study","volume":"133","author":"Mannone","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0100","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.leu.2404291","article-title":"Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm","volume":"20","author":"Mundle","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.11.002_bib0105","series-title":"The Myelodysplastic Syndromes","first-page":"205","article-title":"Cytokines in MDS: abnormalities and treatment","author":"Oster","year":"2011"},{"key":"10.1016\/j.leukres.2016.11.002_bib0110","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3324\/haematol.2010.025015","article-title":"Macrophages as novel target cells for erythropoietin","volume":"95","author":"Lifshitz","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2016.11.002_bib0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.exphem.2012.10.011","article-title":"Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients","volume":"41","author":"Oster","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0120","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","article-title":"Flow cytometric analysis of human bone marrow: II. Normal B lymphocyte development","volume":"70","author":"Loken","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.smim.2003.12.005","article-title":"Human CD4 + CD25+ regulatory t cells","volume":"16","author":"Baecher-Allan","year":"2004","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2016.11.002_bib0135","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"76","article-title":"Chronic myelomonocytic leukaemia","author":"Orazi","year":"2008"},{"key":"10.1016\/j.leukres.2016.11.002_bib0140","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"88","article-title":"Myelodysplastic syndromes\/neoplasms, overview","author":"Brunning","year":"2008"},{"key":"10.1016\/j.leukres.2016.11.002_bib0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1128\/CDLI.3.3.301-304.1996","article-title":"Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation","volume":"3","author":"Simms","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJM198907203210305","article-title":"Treatment of the anemia of progressive renal failure with recombinant human erythropoietin","volume":"321","author":"Eschbach","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.11.002_bib0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000204376","article-title":"Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how: more questions than answers","volume":"90","author":"Mittelman","year":"1993","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000203625","article-title":"Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia","volume":"98","author":"Mittelman","year":"1997","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1525-1594.2009.00948.x","article-title":"Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment","volume":"34","author":"Lisowska","year":"2010","journal-title":"Artif. Organs"},{"key":"10.1016\/j.leukres.2016.11.002_bib0170","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.leukres.2007.03.026","article-title":"Increased apoptosis of circulating T cells in myelodysplastic syndromes","volume":"31","author":"Shioi","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.11.002_bib0175","first-page":"743","article-title":"[Study of Th cell subsets in bone marrow of myelodysplastic syndromes patients]","volume":"26","author":"Wang","year":"2005","journal-title":"Zhonghua xue ye xue za zhi=Zhonghua xueyexue zazhi."},{"key":"10.1016\/j.leukres.2016.11.002_bib0180","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.leukres.2007.10.004","article-title":"The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients","volume":"32","author":"Meers","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.11.002_bib0185","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.exphem.2009.04.009","article-title":"Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset","volume":"37","author":"Fozza","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0190","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","article-title":"Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy","volume":"153","author":"Aggarwal","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.11.002_bib0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.leukres.2012.11.007","article-title":"The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers","volume":"37","author":"Fozza","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.11.002_bib0200","doi-asserted-by":"crossref","first-page":"e1924","DOI":"10.1371\/journal.pone.0001924","article-title":"Erythropoietin: a potent inducer of peripheral Immuno\/Inflammatory modulation in autoimmune EAE","volume":"3","author":"Yuan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2016.11.002_bib0205","first-page":"583","article-title":"Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment","volume":"91","author":"Barrett","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2016.11.002_bib0210","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2003-01-0221","article-title":"Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome","volume":"102","author":"Amin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0215","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/blood-2005-04-1543","article-title":"Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome","volume":"106","author":"Sternberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.002_bib0220","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/01.ASN.0000125618.27422.C7","article-title":"Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin","volume":"15","author":"Roman","year":"2004","journal-title":"J. Am. Soc. Nephrol.: JASN"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T09:41:21Z","timestamp":1718876481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":44,"alternative-id":["S0145212616302429"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.11.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}